Crispr-based SNP detection platform for micronutrient deficiencies

Overview

PathCRISP is an innovative SNP detection platform that combines nucleic acid amplification with CRISPR-Cas12-based detection, providing a highly sensitive and specific solution for identifying single nucleotide polymorphisms (SNPs). Initially developed for Sickle Cell Anemia (SCA), this platform leverages Cas12's sensitivity to single nucleotide mismatches, making it a reliable alternative to traditional methods like Sanger sequencing. PathCRISP is designed to be fast, cost-effective, and easy to use, requiring no cold chain or DNA extraction, making it ideal for decentralized or resource-limited settings.

Technical specifications

Key features:

• Utilizes CRISPR-Cas12-based detection with 100% specificity and sensitivity.
• Two-step process: nucleic acid amplification and CRISPR-based detection.
• Lyophilized reagents enable room-temperature storage and direct use with crude samples such as cheek swabs.
• Fluorescent readout distinguishes between wild-type and mutant alleles, quantified using an app or algorithm.
• Designed for non-invasive sample types and features a rapid, low-cost extraction protocol.
• Aims to extend its application to SNPs linked to micronutrient deficiencies, with in vitro validation and optimization in progress.

Technology readiness level

Currently at TRL 6, PathCRISP has been validated for Sickle Cell genotyping and is undergoing further development to expand its application to SNPs associated with micronutrient deficiencies. The platform is set to become a versatile, user-friendly kit with digital readout integration for broad health and wellness applications.